Assessment of high-normal dosage of Wilate ® compared to placebo administered in combination with platelets to assess reduction of amount of blood loss, need of transfusion products and outcome (length of stay, mortality) in patients with bleeding in comparison.
Age ≥ 18 years
Admission to intensive care unit
Patients needing platelet transfusion during or after surgery with or without prior treatment with single or dual antiplatelet agents (ASS, Prasugrel, Clopidogrel, Ticagrelor)
Consent by the patient or a family member in addition to the consent of an independent ICU physician
Patients receiving Factor VIII concentrate before inclusion of the study (Haemate ®)
Women who are pregnant or breastfeeding
Participation in another study with an investigational drug within the 30 days preceding and during the present study
Overt Disseminated Intravascular Coagulation (DIC)